C19orf33

Across TCGA pan-cancer cohorts, C19orf33 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated C19orf33 data layer compared with 27 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher C19orf33 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated C19orf33 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and HNSC show a favorable association.

GBM, LUAD, and LSCC are the cancer types where C19orf33 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Quartile	All	0.408	0.865	<.001	26	view →
LUAD	OS	Tertile	II,III,IV	0.408	0.827	.005	21	view →
LSCC	OS	Median	All	0.789	0.955	.005	18	view →
PDAC	OS	Quartile	III,IV	0.362	0.968	.011	15	view →
CCRCC	DFS	Quartile	II,III,IV	0.959	0.286	.038	4	view →
HNSC	DFS	Median	IV	0.797	0.566	.011	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

C19orf33–GBM (DFS)

Open the GBM breakdown →